Insmed's BRINSUPRI Approved as First Treatment for Non-Cystic Fibrosis Bronchiectasis in Europe

Insmed's BRINSUPRI Approval: A Historic Step for Non-Cystic Fibrosis Bronchiectasis Treatment in Europe

Insmed Incorporated, a biopharmaceutical company dedicated to developing treatments for serious diseases, celebrates a significant milestone with the European Commission's approval of BRINSUPRI (brensocatib 25 mg tablets) for non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 and older who have experienced two or more exacerbations in the past year. This landmark approval positions BRINSUPRI as the first and only authorized treatment for NCFB within the European Union, reflecting its critical role in addressing a significant public health need. The approval was expedited through the European Medicines Agency's Accelerated Assessment Pathway, underscoring the urgency of delivering effective therapies for this debilitating condition.

NCFB is a chronic and progressive lung disease characterized by dilated airways that lead to the accumulation of mucus and bacteria, which in turn results in persistent inflammation and recurrent infections. This condition affects approximately 600,000 individuals in the EU, with an additional estimated two million who may remain undiagnosed. The impact of NCFB extends beyond physical health, significantly affecting patients' emotional well-being. Professor James Chalmers from the University of Dundee emphasizes the profound effects of this disease on patients' lives, highlighting the essential need for effective treatments like BRINSUPRI.

The approval of BRINSUPRI is based on compelling data from the Phase 3 ASPEN and Phase 2 WILLOW studies, which were published in the New England Journal of Medicine. Results from the ASPEN study demonstrate that patients receiving brensocatib 25 mg experience a 19.4% reduction in the annual rate of exacerbations compared to placebo, as well as notable improvements in the time to first exacerbation and other secondary endpoints. As a pioneering treatment for NCFB, BRINSUPRI not only represents a breakthrough in clinical management but also provides renewed hope for patients seeking better control over their condition and its progression.

In addition to this crucial approval, Insmed continues to engage with healthcare providers to ensure the effective integration of BRINSUPRI into treatment protocols for NCFB. The company's commitment to addressing the needs of patients with serious diseases remains at the forefront of its mission, reinforcing its role as a leader in biopharmaceutical innovation.

As Insmed moves forward, the approval of BRINSUPRI signals a transformative era for NCFB management in Europe, offering a beacon of hope for patients and healthcare systems alike. With ongoing dedication to research and patient care, Insmed is poised to make a lasting impact on the landscape of chronic lung disease treatment.